| |
|
|
|
|
|
|
|||
|
Blood, 1 October 2006, Vol. 108, No. 7, pp. 2463-2469. Prepublished online as a Blood First Edition Paper on June 6, 2006; DOI 10.1182/blood-2006-04-019059.
TRANSPLANTATION Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activityFrom the Integrated Biomedical Sciences Graduate Program; the Department of Internal Medicine, Division of Hematology/Oncology; the Department of Molecular Virology, Immunology, and Medical Genetics; the Division of Epidemiology; the Department of Veterinary Biosciences; the Comprehensive Cancer Center at The Ohio State University, Columbus; the Cancer Center and the Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis.
The "holy grail" of allogeneic stem cell transplantation is to preserve the graft-versus-tumor (GVT) effect while eliminating graft-versus-host disease (GVHD). Endogenous donor-derived interleukin 15 (IL-15) has been implicated in the pathogenesis of acute GVHD, yet the mechanism by which it impacts this lethal process remains unclear. Using the well-described and clinically relevant C57BL/6
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||